Ascendis Pharma (ASND) option IV flat as share price up 19.8%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Tech drags S&P 500, Nasdaq lower as more Iran sanctions, Nvidia earnings loom
- Oil slips ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Tech drags S&P 500, Nasdaq lower as more Iran sanctions, Nvidia earnings loom
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Funds sell $44bn in semiconductors on AI concerns
Ascendis Pharma (ASND) PT Raised to $205 at Evercore ISI
September 17, 2024 6:32 AM EDTEvercore ISI analyst Josh Schimmer raised the price target on Ascendis Pharma (NASDAQ: ASND) to $205.00 (from $191.00) while maintaining a Outperform rating.
The analyst comments "Were still refining some estimates via HCP calls. For now, we model $450M peak TransCON CNP sales in achon. For... More
Ascendis Pharma (ASND) PT Raised to $179 at Jefferies
September 16, 2024 4:35 PM EDTJefferies analyst Kelly Shi raised the price target on Ascendis Pharma (NASDAQ: ASND) to $179.00 (from $174.00) while maintaining a Buy rating.
The analyst comments "Co reported pivotal data from Navepegritide (TransCon CNP) in children w/ achondroplasia aged 2-11yo, which showed an... More
